Loading articles...
Patients with Crohn's disease who experience a primary loss of response to treatment may be identifiable through novel endoscopic parameters. This technology offers the potential for earlier intervention and personalized treatment strategies.
Crohn's disease patients can experience a loss of response to therapy, requiring more intensive interventions. Identifying those at risk early using endoluminal parameters may allow for proactive treatment adjustments and improved outcomes.
In Crohn disease, high-throughput metabolomics profiled prediagnostic biospecimens and revealed pathway-level signatures linked to future diagnosis. Signals across lipid, amino acid, and bile acid metabolism mapped plausible host-microbial axes and preceded...
In Crohn disease, untargeted metabolomics detected pre-diagnostic molecular differences that were associated with future case status, highlighting pathways in lipids, bile acids, amino acids, and microbial co-metabolites. These signals distinguished individ...
In Crohn disease, prediagnostic metabolomics signals point to host-microbiome co-metabolism and lipid and inflammatory mediators as pathways preceding clinical onset. Associations across bile acids, tryptophan derivatives, and sphingolipids suggest early ne...
In Crohn disease, pre-diagnostic metabolomics profiling of biospecimens collected before symptom onset identified metabolites and enriched molecular pathways associated with future incidence. Adjusted associations and pathway-level signals support biologica...